Incidence and nature of infectious disease in patients treated with anti-TNF agents

Autoimmunity Reviews

Volumn 9, Issue 2, 2009, Pages 67-81

  Raychaudhuri, Siba P ^a,b   Nguyen, Caroline T ^b   Raychaudhuri, Smriti K ^a   Gershwin, M Eric ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Opportunistic infection; Rheumatic diseases; TNF; TNF inhibitors; Tuberculosis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CERTOLIZUMAB PEGOL; CHICKENPOX VACCINE; CORTICOSTEROID; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FLUCONAZOLE; GLUCOCORTICOID; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INFLUENZA VACCINE; LAMIVUDINE; MEASLES MUMPS RUBELLA VACCINE; METHOTREXATE; PLACEBO; PREDNISONE; RIBAVIRIN; SIMPONI; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARICELLA ZOSTER VACCINE; YELLOW FEVER VACCINE;

ABSENCE OF SIDE EFFECTS; ANKYLOSING SPONDYLITIS; ASPERGILLOSIS; BACTERIAL INFECTION; BONE INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CROHN DISEASE; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DISEASE ASSOCIATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL INFECTION; GRANULOMATOSIS; HEPATITIS B; HEPATITIS C; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION RISK; INFECTION SENSITIVITY; INFECTIOUS ARTHRITIS; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LISTERIOSIS; LUNG INFECTION; MYCOBACTERIOSIS; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PATIENT MONITORING; PNEUMOCYSTOSIS; PNEUMONIA; POSTOPERATIVE INFECTION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SINGLE DRUG DOSE; SKIN INFECTION; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASES; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350566088     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.08.006     Document Type: Review

References (303)

1. Allaire S., Wolfe F., Niu J., Zhang Y., Zhang B., and LaValley M. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 59 (2008) 1082-1089
2. Aletaha D., Funovits J., Keystone E.C., and Smolen J.S. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56 (2007) 3226-3235
3. Abraham M., Karni A., Dembinsky A., Miller A., Gandhi R., Anderson D., et al. In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J Autoimmun 30 (2008) 21-28
4. Atzeni F., Doria A., Carrabba M., Turiel M., and Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 6 (2007) 529-536
5. Behrens E.M., Finkel T.H., Bradfield J.P., Kim C.E., Linton L., Casalunovo T., et al. Association of the TRAF1-C5 locus on chromosome 9 with juvenile idiopathic arthritis. Arthritis Rheum 58 (2008) 2206-2207
6. Boettger M.K., Hensellek S., Richter F., Gajda M., Stockigt R., von Banchet G.S., et al. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum 58 (2008) 2368-2378
7. Cavazzana I., Ceribelli A., Cattaneo R., and Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 8 (2008) 104-106
8. Conti P., Youinou P., and Theoharides T.C. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev 6 (2007) 131-137
9. Cutolo M., Seriolo B., Pizzorni C., Secchi M.E., Soldano S., Paolino S., et al. Use of glucocorticoids and risk of infections. Autoimmun Rev 8 (2008) 153-155
10. Cutolo M., and Straub R.H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun Rev 7 (2008) 223-228
11. Daridon C., Youinou P., and Pers J.O. BAFF, APRIL, TWE-PRIL: who's who?. Autoimmun Rev 7 (2008) 267-271
12. Galeazzi M., Giannitti C., Manganelli S., Benucci M., Scarpato S., Bazzani C., et al. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 8 (2008) 100-103
13. Gisondi P., and Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 6 (2007) 515-519
14. Gomez-Puerta J.A., Burlingame R.W., and Cervera R. Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun Rev 7 (2008) 606-611
15. Gonnella P.A., Waldner H., Del Nido P.J., and McGowan F.X. Inhibition of experimental autoimmune myocarditis: peripheral deletion of TcR Vbeta 8.1, 8.2+ CD4+ T cells in TLR-4 deficient mice. J Autoimmun 31 (2008) 180-187
16. Ingegnoli F., Fantini F., Favalli E.G., Soldi A., Griffini S., Galbiati V., et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 31 (2008) 175-179
17. Joosten L.A., Helsen M.M., van de Loo F.A., and van den Berg W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum 58 (2008) S110-S122
18. Khoury M., Escriou V., Courties G., Galy A., Yao R., Largeau C., et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum 58 (2008) 2356-2367
19. Lalvani A., and Millington K.A. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 8 (2008) 147-152
20. Liu W., Deyoung B.R., Chen X., Evanoff D.P., and Luo Y. RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model. J Autoimmun 30 (2008) 257-265
21. Liu Z., Jiu J., Liu S., Fa X., Li F., and Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. J Autoimmun 29 (2007) 187-194
22. Middlebrook A.J., Lebsack T., and DeLuca D. TNF-alpha mediated modulation of T cell development and exacerbation of in vitro T1DM in fetal thymus organ culture. J Autoimmun 29 (2007) 134-145
23. Nadareishvili Z., Michaud K., Hallenbeck J.M., and Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 59 (2008) 1090-1096
24. Naredo E., Moller I., Cruz A., Carmona L., and Garrido J. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 58 (2008) 2248-2256
25. Palazzi C., D'Angelo S., and Olivieri I. Hepatitis C virus-related arthritis. Autoimmun Rev 8 (2008) 48-51
26. Patole P.S., Pawar R.D., Lichtnekert J., Lech M., Kulkarni O.P., Ramanjaneyulu A., et al. Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J Autoimmun 29 (2007) 52-59
27. Proulx S.T., Kwok E., You Z., Papuga M.O., Beck C.A., Shealy D.J., et al. Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging. Arthritis Rheum 58 (2008) 2019-2029
28. Punzi L., Podswiadek M., Sfriso P., Oliviero F., Fiocco U., and Todesco S. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 6 (2007) 524-528
29. Reich K., Huffmeier U., Konig I.R., Lascorz J., Lohmann J., Wendler J., et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 56 (2007) 2056-2064
30. Tincani A., Andreoli L., Bazzani C., Bosiso D., and Sozzani S. Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev 7 (2007) 1-7
31. Xue M., March L., Sambrook P.N., and Jackson C.J. Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis. Arthritis Rheum 56 (2007) 2864-2874
32. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3 (2003) 148-155
33. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., and Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003) 2122-2127
34. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
35. Furst D.E., Keystone E.C., Kirkham B., Kavanaugh A., Fleischmann R., Mease P., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67 Suppl 3 (2008) iii2-iii25
36. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
37. Li S., Kaur P.P., Chan V., and Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 28 (2009) 787-791
38. Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Breban M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 60 (2009) 1884-1894
39. Utz J.P., Limper A.H., Kalra S., Specks U., Scott J.P., Vuk-Pavlovic Z., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124 (2003) 177-185
40. Akeno N., Blackard J.T., and Tomer Y. HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J Autoimmun 31 (2008) 339-344
41. Antonelli A., Ferri C., Ferrari S.M., Colaci M., and Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 8 (2008) 18-23
42. Arend W.P., and Goldring M.B. The development of anticytokine therapeutics for rheumatic diseases. Arthritis Rheum 58 (2008) S102-S109
43. Askenasy N., Kaminitz A., and Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 7 (2008) 370-375
44. Baker R.L., Wagner Jr. D.H., and Haskins K. CD40 on NOD CD4 T cells contributes to their activation and pathogenicity. J Autoimmun 31 (2008) 385-392
45. Brucato A., Maestroni S., Cumetti D., Thiella G., Alari G., Brambilla G., et al. Recurrent pericarditis: infectious or autoimmune?. Autoimmun Rev 8 (2008) 44-47
46. Bugatti S., Codullo V., Caporali R., and Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 7 (2007) 137-142
47. Cauvi D.M., Cauvi G., and Pollard K.M. Reduced expression of decay-accelerating factor 1 on CD4+ T cells in murine systemic autoimmune disease. Arthritis Rheum 56 (2007) 1934-1944
48. Doria A., Zampieri S., and Sarzi-Puttini P. Exploring the complex relationships between infections and autoimmunity. Autoimmun Rev 8 (2008) 89-91
49. Ezerzer C., and Harris N. Physiological immunity or pathological autoimmunity - a question of balance. Autoimmun Rev 6 (2007) 488-496
50. Field J., Alderuccio F., Hertzog P., and Toh B.H. GM-CSF-induced autoimmune gastritis in interferon alpha receptor deficient mice. J Autoimmun 31 (2008) 274-280
51. Fiocco U., Sfriso P., Oliviero F., Pagnin E., Scagliori E., Campana C., et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev 8 (2008) 76-82
52. Fujimoto M., Serada S., Mihara M., Uchiyama Y., Yoshida H., Koike N., et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 58 (2008) 3710-3719
53. Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58 (2008) 1505-1515
54. Hillion S., Youinou P., and Jamin C. Peripheral expression of RAG in human B lymphocytes in normal and pathological conditions is dependent on interleukin-6. Autoimmun Rev 6 (2007) 415-420
55. Hoshino A., Nagao T., Nagi-Miura N., Ohno N., Yasuhara M., Yamamoto K., et al. MPO-ANCA induces IL-17 production by activated neutrophils in vitro via classical complement pathway-dependent manner. J Autoimmun 31 (2008) 79-89
56. Kerr E.C., Raveney B.J., Copland D.A., Dick A.D., and Nicholson L.B. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J Autoimmun 31 (2008) 354-361
57. Kwak H.B., Ha H., Kim H.N., Lee J.H., Kim H.S., Lee S., et al. Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 58 (2008) 1332-1342
58. La Cava A. Tregs are regulated by cytokines: implications for autoimmunity. Autoimmun Rev 8 (2008) 83-87
59. Lan R.Y., Selmi C., and Gershwin M.E. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 31 (2008) 7-12
60. Lee E.B., Zhao J., Kim J.Y., Xiong M., and Song Y.W. Evidence of potential interaction of chemokine genes in susceptibility to systemic sclerosis. Arthritis Rheum 56 (2007) 2443-2448
61. Long S.A., and Buckner J.H. Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun 30 (2008) 293-302
62. Mamyrova G., O'Hanlon T.P., Sillers L., Malley K., James-Newton L., Parks C.G., et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 58 (2008) 3941-3950
63. Munoz L.E., Gaipl U.S., and Herrmann M. Predictive value of anti-dsDNA autoantibodies: importance of the assay. Autoimmun Rev 7 (2008) 594-597
64. Omersel J., Jurgec I., Cucnik S., Kveder T., Rozman B., Sodin-Semrl S., et al. Autoimmune and proinflammatory activity of oxidized immunoglobulins. Autoimmun Rev 7 (2008) 523-529
65. Payne N., Siatskas C., and Bernard C.C. The promise of stem cell and regenerative therapies for multiple sclerosis. J Autoimmun 31 (2008) 288-294
66. Pisetsky D.S. The role of innate immunity in the induction of autoimmunity. Autoimmun Rev 8 (2008) 69-72
67. Romani L. Parasites and autoimmunity: the case of fungi. Autoimmun Rev 8 (2008) 129-133
68. Scaglione B.J., Salerno E., Gala K., Pan M., Langer J.A., Mostowski H.S., et al. Regulatory T cells as central regulators of both autoimmunity and B cell malignancy in New Zealand Black mice. J Autoimmun 32 (2009) 14-23
69. Seydel F., Garrigan E., Stutevoss B., Belkin N., Makadia B., Carter J., et al. GM-CSF induces STAT5 binding at epigenetic regulatory sites within the Csf2 promoter of non-obese diabetic (NOD) mouse myeloid cells. J Autoimmun 31 (2008) 377-384
70. Vital E.M., and Emery P. The development of targeted therapies in rheumatoid arthritis. J Autoimmun 31 (2008) 219-227
71. Wang D., Drenker M., Eiz-Vesper B., Werfel T., and Wittmann M. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum 58 (2008) 3205-3215
72. Zayed N., Afif H., Chabane N., Mfuna-Endam L., Benderdour M., Martel-Pelletier J., et al. Inhibition of interleukin-1beta-induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D2. Arthritis Rheum 58 (2008) 3530-3540
73. Zhou Y., and Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev 7 (2008) 376-383
74. Zigmond E., Shalev Z., Pappo O., Alper R., Zolotarov L., and Ilan Y. NKT lymphocyte polarization determined by microenvironment signaling: a role for CD8+ lymphocytes and beta-glycosphingolipids. J Autoimmun 31 (2008) 188-195
75. Beutler B., and Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Annu Rev Immunol 7 (1989) 625-655
76. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 19 (2001) 163-196
77. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 (1995) 561-572
78. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., and Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168 (2002) 4620-4627
79. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38 (1995) 499-505
80. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
81. Allendoerfer R., and Deepe Jr. G.S. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 160 (1998) 6072-6082
82. Huffnagle G.B., Toews G.B., Burdick M.D., Boyd M.B., McAllister K.S., McDonald R.A., et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 157 (1996) 4529-4536
83. Marino M.W., Dunn A., Grail D., Inglese M., Noguchi Y., Richards E., et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 94 (1997) 8093-8098
84. Mehrad B., Strieter R.M., and Standiford T.J. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 162 (1999) 1633-1640
85. Randhawa P.S. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 22 (1990) 153-155
86. Algood H.M., Lin P.L., and Flynn J.L. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41 Suppl 3 (2005) S189-S193
87. Rothe J., Lesslauer W., Lotscher H., Lang Y., Koebel P., Kontgen F., et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364 (1993) 798-802
88. Deepe Jr. G.S. Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 41 Suppl 3 (2005) S204-S207
89. O'Brien D.P., Briles D.E., Szalai A.J., Tu A.H., Sanz I., and Nahm M.H. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 67 (1999) 595-601
90. Moore T.A., Lau H.Y., Cogen A.L., and Standiford T.J. Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha. Clin Infect Dis 41 Suppl 3 (2005) S213-S217
91. Wallis R.S., Broder M., Wong J., and Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39 (2004) 1254-1255
92. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., and Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
93. Crum N.F., Lederman E.R., and Wallace M.R. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84 (2005) 291-302
94. Kroesen S., Widmer A.F., Tyndall A., and Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42 (2003) 617-621
95. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
96. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
97. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30 (2003) 2563-2571
98. van de Putte L.B., Rau R., Breedveld F.C., Kalden J.R., Malaise M.G., van Riel P.L., et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 62 (2003) 1168-1177
99. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594-1602
100. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
101. Solomon D.H., Lunt M., and Schneeweiss S. The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. Arthritis Rheum 58 (2008) 919-928
102. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Thomsen O.O., Hanauer S.B., McColm J., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007) 239-250
103. Dixon W., and Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther 8 (2006) 111
104. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005) 3403-3412
105. Greenberg J.D., Reed G., Kremer J., Tindall E., Kavanaugh A., Zheng C., et al. Association of methotrexate and TNF antagonists with risk of infection outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis (2009) Electronic publication ahead of print
106. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., and Symmons D.P. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
107. Wolfe F., Caplan L., and Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54 (2006) 628-634
108. Favalli E.G., Desiati F., Atzeni F., Sarzi-Puttini P., Caporali R., Pallavicini F.B., et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 8 (2009) 266-273
109. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 14 (1971) 135-137
110. Hernandez-Cruz B., Cardiel M.H., Villa A.R., and Alcocer-Varela J. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 25 (1998) 1900-1907
111. Mutru O., Laakso M., Isomaki H., and Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 290 (1985) 1797-1799
112. Wolfe F., Mitchell D.M., Sibley J.T., Fries J.F., Bloch D.A., Williams C.A., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 37 (1994) 481-494
113. Lonnroth K., and Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 29 (2008) 481-491
114. Dye C., Scheele S., Dolin P., Pathania V., and Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282 (1999) 677-686
115. Kindler V., Sappino A.P., Grau G.E., Piguet P.F., and Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56 (1989) 731-740
116. Senaldi G., Yin S., Shaklee C.L., Piguet P.F., Mak T.W., and Ulich T.R. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 157 (1996) 5022-5026
117. Turner J., Frank A.A., Brooks J.V., Marietta P.M., and Orme I.M. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 102 (2001) 248-253
118. Mohan V.P., Scanga C.A., Yu K., Scott H.M., Tanaka K.E., Tsang E., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 69 (2001) 1847-1855
119. Fonseca J.E., Canhao H., Silva C., Miguel C., Mediavilla M.J., Teixeira A., et al. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience. Acta Reumatol Port 31 (2006) 247-253
120. Brassard P., Kezouh A., and Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43 (2006) 717-722
121. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Coster L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005) 1986-1992
122. Tubach F., Salmon-Ceron D., Ravaud P., and Mariette X. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine 72 (2005) 456-460
123. Smolen J.S., Keystone E.C., Emery P., Breedveld F.C., Betteridge N., Burmester G.R., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 143-150
124. (CDC) CfDCaP. Trends in tuberculosis - United States, 1998-2003. MMWR Morb Mortal Wkly Rep vol. 53 (2004) 209-214
125. Raval A., Akhavan-Toyserkani G., Brinker A., and Avigan M. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 147 (2007) 699-702
126. Wolfe F., Michaud K., Anderson J., and Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50 (2004) 372-379
127. Carmona L., Hernandez-Garcia C., Vadillo C., Pato E., Balsa A., Gonzalez-Alvaro I., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30 (2003) 1436-1439
128. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?. Clin Infect Dis 41 Suppl 3 (2005) S199-S203
129. Wallis R.S., Kyambadde P., Johnson J.L., Horter L., Kittle R., Pohle M., et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18 (2004) 257-264
130. Ringheanu M., Daum F., Markowitz J., Levine J., Katz S., Lin X., et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 10 (2004) 801-810
131. Saliu O.Y., Sofer C., Stein D.S., Schwander S.K., and Wallis R.S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194 (2006) 486-492
132. Tuberculosis associated withh blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb Mortal Wkly Rep vol. 53 (2004) 683
133. Mazurek G.H., Jereb J., Lobue P., Iademarco M.F., Metchock B., and Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (2005) 49-55
134. Arend S.M., Leyten E.M., Franken W.P., Huisman E.M., and van Dissel J.T. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 45 (2007) 1470-1475
135. Hamilton C.D. Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum 48 (2003) 2085-2091
136. Hill P.C., Brookes R.H., Fox A., Fielding K., Jeffries D.J., Jackson-Sillah D., et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 38 (2004) 966-973
137. Greenberg J.D., Reddy S.M., Schloss S.G., Kurucz O.S., Bartlett S.J., Abramson S.B., et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 35 (2008) 770-775
138. Brock I., Weldingh K., Lillebaek T., Follmann F., and Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 170 (2004) 65-69
139. Treatment of tuberculosis. MMWR Recomm Rep 52 (2003) 1-77
140. Mariette X., Salmon D., and Group RATIO. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62 (2004) 791
141. Furst D.E., Cush J., Kaufmann S., Siegel J., and Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 61 Suppl 2 (2002) ii62-ii63
142. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52 (2005) 1766-1772
143. Winthrop K.L., Yamashita S., Beekmann S.E., and Polgreen P.M. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 46 (2008) 1738-1740
144. Dare J.A., Jahan S., Hiatt K., and Torralba K.D. Reintroduction of etanercept during treatment of cutaneous Mycobacterium marinum infection in a patient with ankylosing spondylitis. Arthritis Rheum 61 (2009) 583-586
145. Furst D.E., Keystone E., Maini R.N., and Smolen J.S. Recapitulation of the round-table discussion - assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 38 Suppl 2 (1999) 50-53
146. Jones R.E., and Moreland L.W. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 48 (1999) 1-4
147. Kavanaugh A.F. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 24 (1998) 593-614
148. Culy C.R., and Keating G.M. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62 (2002) 2493-2537
149. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Bijl H., et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344 (1994) 1125-1127
150. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36 (1993) 1681-1690
151. Bang L.M., and Keating G.M. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 18 2 (2004) 121-139 Review.
152. Breedveld F.C., Emery P., Keystone E., Patel K., Furst D.E., Kalden J.R., et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63 (2004) 149-155
153. Fleischmann R.M., Iqbal I., and Stern R.L. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 3 (2004) 391-403
154. Harriman G., Harper L.K., and Schaible T.F. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis 58 Suppl 1 (1999) I61-I64
155. Burmester G.R. Long term efficacy and safety of adelimumab monotherapy in patients with DMARD-refractory RA: results from a two year study. Arthritis Rheum (2002) s537
156. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46 (2002) 1443-1450
157. Hyrich K.L., Silman A.J., Watson K.D., and Symmons D.P. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63 (2004) 1538-1543
158. Khanna D., McMahon M., and Furst D.E. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27 (2004) 307-324
159. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
160. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., Schneider U., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52 (2005) 1227-1236
161. Lee J.H., Slifman N.R., Gershon S.K., Edwards E.T., Schwieterman W.D., Siegel J.N., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46 (2002) 2565-2570
162. Manadan A.M., Block J.A., and Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 21 (2003) 526
163. Slifman N.R., Gershon S.K., Lee J.H., Edwards E.T., and Braun M.M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 48 (2003) 319-324
164. Jain V.V., Evans T., and Peterson M.W. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med 100 (2006) 1291-1293
165. Bergstrom L., Yocum D.E., Ampel N.M., Villanueva I., Lisse J., Gluck O., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50 (2004) 1959-1966
166. Giles J.T., and Bathon J.M. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 19 (2004) 320-334
167. Strangfeld A., and Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 20 (2006) 1181-1195
168. Wheat L.J., and Kauffman C.A. Histoplasmosis. Infect Dis Clin North Am 17 1-19 (2003) vii
169. Morgan J., Cano M.V., Feikin D.R., et al. A large outbreak of histoplasmosis among American travelers associated with a hotel in Acapulco, Mexico, spring 2001. Am J Trop Med Hyg 69 6 (2003 Dec) 663-669
170. US Food Committee Drug Administration Arthritis Advisory. Briefing information (2009). http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm. Accessed July
171. Allendoerfer R., and Deepe G.J. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 160 12 (1998 Jun 15) 6072-6082
172. Woods J.P. Histoplasma capsulatum molecular genetics, pathogenesis, and responsiveness to its environment. Fungal Genet Biol 35 (2002) 81-97
173. McKinsey D.S., Spiegel R.A., Hutwagner L., Stanford J., Driks M.R., Brewer J., et al. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis 24 (1997) 1195-1203
174. Wheat J. Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore) 76 (1997) 339-354
175. Crum N.F., Lederman E.R., Stafford C.M., Parrish J.S., and Wallace M.R. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) 83 (2004) 149-175
176. Chu J.H., Feudtner C., Heydon K., Walsh T.J., and Zaoutis T.E. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 42 (2006) 822-825
177. Blair J.E., Douglas D.D., and Mulligan D.C. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis 5 (2003) 3-8
178. Levitz S.M. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 13 (1991) 1163-1169
179. Bauman S.K., Huffnagle G.B., and Murphy J.W. Effects of tumor necrosis factor alpha on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the anticryptococcal cell-mediated immune response. Infect Immun 71 (2003) 68-74
180. Altz-Smith M., Kendall Jr. L.G., and Stamm A.M. Cryptococcosis associated with low-dose methotrexate for arthritis. Am J Med 83 (1987) 179-181
181. Kaplan J.E., Masur H., and Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 51 (2002) 1-52
182. Hage C.A., Wood K.L., Winer-Muram H.T., Wilson S.J., Sarosi G., and Knox K.S. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 124 (2003) 2395-2397
183. Shrestha R.K., Stoller J.K., Honari G., Procop G.W., and Gordon S.M. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care 49 (2004) 606-608
184. Warris A., Bjorneklett A., and Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 344 (2001) 1099-1100
185. van der Klooster J.M., Bosman R.J., Oudemans-van Straaten H.M., van der Spoel J.I., Wester J.P., and Zandstra D.F. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 29 (2003) 2327-2329
186. CDC disease information. Listeriosis (2009). http://www.cdc.gov/nczved/dfbmd/disease_listing/listeriosis_gi.html http://www.cdc.gov/nczved/dfbmd/disease_listing/listeriosis_gi.html. Accessed July
187. Wing E.J., and Gregory S.H. Listeria monocytogenes: clinical and experimental update. J Infect Dis 185 Suppl 1 (2002) S18-S24
188. Beretich Jr. G.R., Carter P.B., and Havell E.A. Roles for tumor necrosis factor and gamma interferon in resistance to enteric listeriosis. Infect Immun 66 (1998) 2368-2373
189. Kato K., Nakane A., Minagawa T., Kasai N., Yamamoto K., Sato N., et al. Human tumor necrosis factor increases the resistance against Listeria infection in mice. Med Microbiol Immunol 178 (1989) 337-346
190. Nakane A., Minagawa T., Kohanawa M., Chen Y., Sato H., Moriyama M., et al. Interactions between endogenous gamma interferon and tumor necrosis factor in host resistance against primary and secondary Listeria monocytogenes infections. Infect Immun 57 (1989) 3331-3337
191. Nishikawa S., Miura T., Sasaki S., and Nakane A. The protective role of endogenous cytokines in host resistance against an intragastric infection with Listeria monocytogenes in mice. FEMS Immunol Med Microbiol 16 (1996) 291-298
192. Pfeffer K., Matsuyama T., Kundig T.M., Wakeham A., Kishihara K., Shahinian A., et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73 (1993) 457-467
193. Aparicio A.G., Munoz-Fernandez S., Bonilla G., Miralles A., Cerdeno V., and Martin-Mola E. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al. Arthritis Rheum vol. 48 (2003) 1764-1765 author reply 5-6
194. Bowie V.L., Snella K.A., Gopalachar A.S., and Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 38 (2004) 58-61
195. Pagliano P., Attanasio V., Fusco U., Mohamed D.A., Rossi M., and Faella F.S. Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis?. Ann Rheum Dis 63 (2004) 462-463
196. Pifer L.L., Hughes W.T., Stagno S., and Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 61 (1978) 35-41
197. Dohn M.N., White M.L., Vigdorth E.M., Ralph Buncher C., Hertzberg V.S., Baughman R.P., et al. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection. Am J Respir Crit Care Med 162 (2000) 1617-1621
198. Kolls J.K., Lei D., Vazquez C., Odom G., Summer W.R., Nelson S., et al. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol Biol 16 (1997) 112-118
199. Kaur N., and Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 52 (2007) 1481-1484
200. Harigai M., Koike R., and Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 357 (2007) 1874-1876
201. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
202. Dombrovskiy V.Y., Martin A.A., Sunderram J., and Paz H.L. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35 (2007) 1244-1250
203. Abraham E., Wunderink R., Silverman H., Perl T.M., Nasraway S., Levy H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273 (1995) 934-941
204. Cohen J., and Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24 (1996) 1431-1440
205. Abraham E., Glauser M.P., Butler T., Garbino J., Gelmont D., Laterre P.F., et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277 (1997) 1531-1538
206. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 25 (1999) 556-566
207. Fisher Jr. C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334 (1996) 1697-1702
208. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
209. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
210. Moreland L.W., Cohen S.B., Baumgartner S.W., Tindall E.A., Bulpitt K., Martin R., et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 28 (2001) 1238-1244
211. Kling A., Mjorndal T., and Rantapaa-Dahlqvist S. Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNFalpha antagonists. J Clin Rheumatol 10 (2004) 119-122
212. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
213. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13 (1995) 29-60
214. Torre D., Zeroli C., Giola M., Ferrario G., Fiori G.P., Bonetta G., et al. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis 18 (1994) 194-198
215. Fang J.W., Shen W.W., Lau A., and Meager J.Y. Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol 91 (1996) 748-753
216. Ganem D., and Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
217. Hohler T., Kruger A., Gerken G., Schneider P.M., Meyer zum Buschenefelde K.H., and Rittner C. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 111 (1998) 579-582
218. Su F., and Schneider R.J. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci U S A 94 (1997) 8744-8749
219. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., and Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4 (1996) 25-36
220. Guidotti L.G., Ando K., Hobbs M.V., Ishikawa T., Runkel L., Schreiber R.D., et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 91 (1994) 3764-3768
221. Pasquetto V., Wieland S.F., Uprichard S.L., Tripodi M., and Chisari F.V. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 76 (2002) 5646-5653
222. Wendling D., Auge B., Bettinger D., Lohse A., Le Huede G., Bresson-Hadni S., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64 (2005) 788-789
223. Numata Y., Tazuma S., Ueno Y., Nishioka T., Hyogo H., and Chayama K. Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis. Dig Dis Sci 50 (2005) 1844-1851
224. Ueno Y., Tanaka S., Shimamoto M., Miyanaka Y., Hiyama T., Ito M., et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 50 (2005) 163-166
225. Ostuni P., Botsios C., Punzi L., Sfriso P., and Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62 (2003) 686-687
226. Michel M., Duvoux C., Hezode C., and Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 30 (2003) 1624-1625
227. Esteve M., Saro C., Gonzalez-Huix F., Suarez F., Forne M., and Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004) 1363-1365
228. Carroll M.B., and Bond M.I. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38 (2008) 208-217
229. Wasley A., Grytdal S., and Gallagher K. Surveillance for acute viral hepatitis - United States, 2006. MMWR Surveill Summ 57 (2008) 1-24
230. Nelson D.R., Lim H.L., Marousis C.G., Fang J.W., Davis G.L., Shen L., et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 42 (1997) 2487-2494
231. Kallinowski B., Haseroth K., Marinos G., Hanck C., Stremmel W., Theilmann L., et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 111 (1998) 269-277
232. Monsalve-De Castillo F., Romero T.A., Estevez J., Costa L.L., Atencio R., Porto L., et al. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol 9 (2002) 1372-1375
233. del Valle Garcia-Sanchez M., Gomez-Camacho F., Poyato-Gonzalez A., Iglesias-Flores E.M., and de Dios-Vega JF Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10 (2004) 701-702
234. Oniankitan O., Duvoux C., Challine D., Mallat A., Chevalier X., Pawlotsky J.M., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31 (2004) 107-109
235. Magliocco M.A., and Gottlieb A.B. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 (2004) 580-584
236. Parke F.A., and Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51 (2004) 800-804
237. Peterson J.R., Hsu F.C., Simkin P.A., and Wener M.H. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003) 1078-1082
238. Campbell S., and Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 13 (2001) 191-192
239. Holtmann M.H., Galle P.R., and Neurath M.F. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 98 (2003) 504-505
240. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42 (2005) 315-322
241. Zylberberg H., Rimaniol A.C., Pol S., Masson A., De Groote D., Berthelot P., et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30 (1999) 185-191
242. Calabrese L.H., Zein N., and Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63 Suppl 2 (2004) ii18-ii24
243. Aslanidis S., Vassiliadis T., Pyrpasopoulou A., Douloumpakas I., and Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 26 (2007) 261-264
244. Kaur P.P., Chan V.C., and Berney S.N. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J Clin Rheumatol 13 (2007) 79-80
245. Cepeda E.J., Williams F.M., Ishimori M.L., Weisman M.H., and Reveille J.D. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 67 (2008) 710-712
246. Walker R.E., Spooner K.M., Kelly G., McCloskey R.V., Woody J.N., Falloon J., et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 174 (1996) 63-68
247. Sha B.E., Valdez H., Gelman R.S., Landay A.L., Agosti J., Mitsuyasu R., et al. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses 18 (2002) 661-665
248. Chan A.T., Cleeve V., and Daymond T.J. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 78 (2002) 47-48
249. Olivieri I., Padula A., Armignacco L., Sabatella V., and Mancino M. Septic arthritis caused by Moraxella catarrhalis associated with infliximab treatment in a patient with undifferentiated spondarthritis. Ann Rheum Dis 63 (2004) 105-106
250. Reichardt P., Dahnert I., Tiller G., and Hausler H.J. Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus) after treatment with infliximab in a boy with Crohn's disease. Eur J Pediatr 161 (2002) 281-283
251. Baumgart D.C., and Dignass A.U. Shingles following infliximab infusion. Ann Rheum Dis 61 (2002) 661
252. Cursiefen C., Grunke M., Dechant C., Antoni C., Junemann A., and Holback L.M. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNF-alpha-antibody and methotrexate therapy. Am J Ophthalmol (2002) 270-271
253. Helbling D., Breitbach T.H., and Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 14 (2002) 1393-1395
254. van der Klooster J.M., Bosman R.J., Oudemans-van Straaten H.M., van der Spoel J.I., Wester J.P., and Zandstra D.F. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med (2003) 2327-2329
255. van der Heijde D., Kivitz A., Schiff M.H., Sieper J., Dijkmans B.A., Braun J., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54 (2006) 2136-2146
256. Davis Jr. J.C., Van Der Heijde D., Braun J., Dougados M., Cush J., Clegg D.O., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48 (2003) 3230-3236
257. Keystone E.C. Safety of biologic therapies - an update. J Rheumatol Suppl 74 (2005) 8-12
258. Salliot C., Gossec L., Ruyssen-Witrand A., Luc M., Duclos M., Guignard S., et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 46 (2007) 327-334
259. Genovese M.C., Cohen S., Moreland L., Lium D., Robbins S., Newmark R., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50 (2004) 1412-1419
260. Weinblatt M., Schiff M., Goldman A., Kremer J., Luggen M., Li T., et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 66 (2007) 228-234
261. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., and Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006) 2807-2816
262. Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol 2 (2003) 375-377
263. Filler S.G., Yeaman M.R., and Sheppard D.C. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis 41 Suppl 3 (2005) S208-S212
264. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., and Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46 (2002) 2287-2293
265. Furst D.E., Wallis R., Broder M., and Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36 (2006) 159-167
266. Mohan A.K., Cote T.R., Block J.A., Manadan A.M., Siegel J.N., and Braun M.M. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39 (2004) 295-299
267. Davis J.C., van der Heijde D.M., Braun J., Dougados M., Cush J., Clegg D., et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64 (2005) 1557-1562
268. Netea M.G., Radstake T., Joosten L.A., van der Meer J.W., Barrera P., and Kullberg B.J. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 48 (2003) 1853-1857
269. Sipsas N.V., Papaparaskevas J., Stefanou I., Kalatzis K., Vlachoyiannopoulos P., and Avlamis A. Septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy. Diagn Microbiol Infect Dis 55 (2006) 343-345
270. Giles J.T., Bartlett S.J., Gelber A.C., Nanda S., Fontaine K., Ruffing V., et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 55 (2006) 333-337
271. Kapetanovic M.C., Saxne T., Nilsson J.A., and Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 46 (2007) 608-611
272. Fomin I., Caspi D., Levy V., Varsano N., Shalev Y., Paran D., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 65 (2006) 191-194
273. Baschal E.E., and Eisenbarth G.S. Extreme genetic risk for type 1A diabetes in the post-genome era. J Autoimmun 31 (2008) 1-6
274. Castro J., Balada E., Ordi-Ros J., and Vilardell-Tarres M. The complex immunogenetic basis of systemic lupus erythematosus. Autoimmun Rev 7 (2008) 345-351
275. Etzensperger R., McMahon R.M., Jones E.Y., and Fugger L. Dissection of the multiple sclerosis associated DR2 haplotype. J Autoimmun 31 (2008) 201-207
276. Foreman A.L., Van de Water J., Gougeon M.L., and Gershwin M.E. B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage. Autoimmun Rev 6 (2007) 387-401
277. Frazer I.H. Autoimmunity and persistent viral infection: two sides of the same coin?. J Autoimmun 31 (2008) 216-218
278. Harrison L.C., Honeyman M.C., Morahan G., Wentworth J.M., Elkassaby S., Colman P.G., et al. Type 1 diabetes: lessons for other autoimmune diseases?. J Autoimmun 31 (2008) 306-310
279. Hudson M., Rojas-Villarraga A., Coral-Alvarado P., Lopez-Guzman S., Mantilla R.D., Chalem P., et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 31 (2008) 156-159
280. Jordan M.A., and Baxter A.G. The genetics of immunoregulatory T cells. J Autoimmun 31 (2008) 237-244
281. Mackay I.R., Leskovsek N.V., and Rose N.R. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 30 (2008) 5-11
282. Martinsson K., Carlsson L., Kleinau S., and Hultman P. The effect of activating and inhibiting Fc-receptors on murine mercury-induced autoimmunity. J Autoimmun 31 (2008) 22-29
283. Meroni P.L. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J Autoimmun 30 (2008) 99-103
284. Morahan G., Peeva V., Mehta M., and Williams R. Systems genetics can provide new insights in to immune regulation and autoimmunity. J Autoimmun 31 (2008) 233-236
285. Ooi J.D., Holdsworth S.R., and Kitching A.R. Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells. J Autoimmun 31 (2008) 295-300
286. Pai S., and Thomas R. Immune deficiency or hyperactivity-Nf-kappab illuminates autoimmunity. J Autoimmun 31 (2008) 245-251
287. Ross C.J., Katzov H., Carleton B., and Hayden M.R. Pharmacogenomics and its implications for autoimmune disease. J Autoimmun 28 (2007) 122-128
288. Sanchez-Pernaute O., Ospelt C., Neidhart M., and Gay S. Epigenetic clues to rheumatoid arthritis. J Autoimmun 30 (2008) 12-20
289. Tomer Y., Menconi F., Davies T.F., Barbesino G., Rocchi R., Pinchera A., et al. Dissecting genetic heterogeneity in autoimmune thyroid diseases by subset analysis. J Autoimmun 29 (2007) 69-77
290. Boren E.J., Cheema G.S., Naguwa S.M., Ansari A.A., and Gershwin M.E. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 30 (2008) 90-98
291. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66 (2007) 1339-1344
292. Askling J. Risk for tuberculosis following treatment of rheumatoid arthritis with anti-TNF therapy - the Swedish experience 1998-2008. Ann Rheum Dis 68 suppl3 (2009) 422
293. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
294. Dixon WG, Hyrich KL, Watson KD, Lunt M. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSR Biologics Register (BSRBR). American College of Rheumatology 2008 Annual Scientific Meeting: October 24-29, 2008; San Francisco, CA. Arthritis Rheum 2008; Abstract THU0134.
295. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005;84:291-302.
296. Hinshaw LB, Emerson Jr. TE, Taylor Jr. FB, Chang AC, Duerr M, Peer GT, et al. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. The Journal of Trauma 1992 Oct;33(4):568-73.
297. Lavancy D, McMahon B. Worldwide prevalence and prevention of hepatitis C. In: Liang TJ, Hoofnagle JH, editors. Hepatitis C. San Diego: Academic Press; 2000, pp. 186-201.
298. Vassilopoulos D, Calabrese LH. Rheumatic aspects of human immunodeficiency virus infection and other immunodeficient states. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. London: Mosby; 2003, pp. 1115-1129.
299. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
300. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
301. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971;14:135-7.
302. Hernandez-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 1998;25:1900-7.
303. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.